Patents Assigned to Hadasit Medical Research Services & Development Limited
  • Patent number: 7766850
    Abstract: A brace for correction of scoliosis is disclosed, comprising at least one thoracic shell element and a pelvic shell element and at least one working element having a main longitudinal axis to be oriented parallel to the trunk to be treated, anchored on one of its opposite ends to the thoracic shell element and on the other to the pelvic shell element, and having spring characteristics adapted to apply continuous de-rotational force about said longitudinal axis.
    Type: Grant
    Filed: September 5, 2004
    Date of Patent: August 3, 2010
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventor: Naum Simanovsky
  • Patent number: 7744920
    Abstract: The present invention provides the use of a glucocorticoid (GC) or of a GC derivative encapsulated in a liposome for the preparation of a pharmaceutical composition for the treatment of an inflammatory associated condition in a subject, provided that said condition is not associated with a neurodegenerative disease or disorder. A specific use concerns a liposomal formulation comprising methylprednisolone sodium hemisuccinate (MPS) for the treatment of rheumatoid arthritis.
    Type: Grant
    Filed: September 11, 2005
    Date of Patent: June 29, 2010
    Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University
    Inventors: Yechezkel Barenholz, Yaakov Naparstek, Yuval Avnir, Rina Ulmansky
  • Publication number: 20100159012
    Abstract: The present invention discloses modified polymer conjugates of a polymer and a drug having reduced toxicity relative to the unmodified parent compound while retaining substantially the same degree of therapeutic activity as of the unmodified parent compound.
    Type: Application
    Filed: September 26, 2006
    Publication date: June 24, 2010
    Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Abraham J. Domb, Itzhack Polacheck, Marina Sokolsky, Jacob Golenser
  • Publication number: 20100098749
    Abstract: The present invention concerns methods of joint lubrication and/or prevention of cartilage wear making use of liposomes having membranes with at least one phospholipid (PL) of the group consisting of a glycerophospholipid (GPL) having two, being the same or different, C12-C16 hydrocarbon chain and a sphingolipid (SPL) having a C12-C15 hydrocarbon chain, the one or more membranes having a phase transition temperature in which solid ordered (SO) to liquid disordered (LD) phase transition occurs, the phase transition temperature being within a temperature of about 20° C. to about 39° C. for lubrication of joints.
    Type: Application
    Filed: March 26, 2009
    Publication date: April 22, 2010
    Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED, TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Yechezkel BARENHOLZ, Dorit NITZAN, Izhak ETSION, Avi SCHROEDER, Grigory HALPERIN, Sarit SIVAN
  • Publication number: 20100093091
    Abstract: The present disclosure provides methods for maintaining and propagating undifferentiated pluripotent stem cells (SC) in suspension. The methods comprise culturing such SC in a non-adherent culture dish under conditions comprising a basic serum free medium and one or more of a basic medium, a serum replacement, an extra cellular matrix component and a factor supporting expansion of said SC. A specific and preferred culture condition comprise supplementing Neurobasal™ medium with KO serum replacement (KOSR). These conditions allowed for large scale and long term propagation of undifferentiated pluripotent SC. The culture system comprising suspended undifferentiated pluripotent SC were found to have many applications including in methods for directed as well as spontaneous differentiation of the SC into somatic cells. Also disclosed herein is a method of deriving SC, preferably human embryonic SC from human embryos via the formation of cell clusters.
    Type: Application
    Filed: September 30, 2009
    Publication date: April 15, 2010
    Applicant: Hadasit Medical Research Services & Development Limited
    Inventors: Benjamin Reubinoff, Debora Steiner
  • Publication number: 20090304587
    Abstract: The present invention discloses composites which generally comprise a polymeric matrix and a hydrophobic organic compound which is associated with a radioisotope.
    Type: Application
    Filed: November 1, 2006
    Publication date: December 10, 2009
    Applicants: Yissum Research Development Company Of The Hebrew University of Jerusalem, Hadasit Medical Research Services & Development Limited
    Inventors: Abraham Rubinstein, Abdel Kareem Azab, Boris Orkin, Aviram Nissan, Susan Haupt, Morris Srebnki, Raphael Udassin
  • Publication number: 20080045474
    Abstract: A method for treating metastatic tumor cells of a subject is disclosed. The method comprises administrating to the subject an antisense molecule comprising a nucleotide sequence which is complementary to an RNA sequence of a protease activated receptor (PAR) protein, or an antibody molecule capable of binding to a PAR protein. A method is also described for the treatment of disorders involving the implantation of a placenta in a female subject comprising administrating to the subject the antisense molecule. Also disclosed is the antisense molecule and a pharmaceutical composition comprising it.
    Type: Application
    Filed: April 19, 2007
    Publication date: February 21, 2008
    Applicant: Hadasit Medical Research Services & Development Limited
    Inventor: Rachel Bar-Shavit
  • Patent number: 6461611
    Abstract: Pharmaceutical compositions for the treatment of a decrease in the levels of protease activated receptor (PAR) mRNA caused by a lack or decrease of oxygen level and/or a lack or decrease of blood flow including pharmaceutically acceptable carriers and activators of PAR are provided. Methods for prevention of a decrease in the levels of protease-activated receptor PAR mRNA caused by lack or decrease in the oxygen level and/or lack or decrease in blood flow are also provided.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: October 8, 2002
    Assignee: Hadasit Medical Research Services & Development Limited
    Inventor: Rachel Bar-Shavit
  • Patent number: 6442423
    Abstract: The present invention concerns a device (10) for administration of charged drugs to the eye comprising an applicator with a receiving portion for holding a hydrogel carrier loaded with the drug. The device also comprises an electric current generating element (15, 13, 14) for generating currents not exceeding 1000 &mgr;Amp coupled to a timing element (11) which ensures that currents do not last more than 120 secs.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: August 27, 2002
    Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Abraham Domb, Joseph Frucht-Perry, Mervyn Shapiro